最新调仓路径显现 基金经理关注确定性与安全边际

Group 1 - The core viewpoint of the article highlights significant portfolio adjustments by well-known fund managers in anticipation of growth in sectors like AI, non-ferrous metals, and lithium battery materials for 2026 [1][4] - Fund manager Fu Pengbo indicates that high-growth sectors such as AI and non-ferrous metals will see substantial growth, while manager Li Xiaoxing emphasizes that AI remains the main theme of global technological innovation [1][7] - Manager Yang Jinjing advocates for avoiding currently popular but overvalued sectors, focusing instead on blue-chip stocks that are expected to show long-term performance turning points [1][5] Group 2 - In the fourth quarter of 2025, the top ten holdings of the Ruiyuan Growth Value Fund managed by Fu Pengbo and Zhu Lin saw minor changes, with Maiwei Co. replacing China Mobile, and significant adjustments in holdings of companies like Tencent and Alibaba [2] - The Silver华心怡 Fund, managed by Li Xiaoxing and Zhang Ping, underwent substantial adjustments, with new entries including Tencent, Alibaba, and Meituan, while exiting positions in China Mobile and HSBC [2] - The Yongying Ruixin Fund, managed by Gao Nan, also made notable adjustments, adding companies like WISCO and Haier, while reducing positions in companies like Zhongji Xuchuang [3] Group 3 - Fu Pengbo and Zhu Lin plan to reduce investments in companies with weak fundamentals and increase holdings in data center-related companies based on industry trends and individual stock research [2][4] - Gao Nan focuses on company growth potential and performance realization, aiming for a diversified portfolio while capturing growth opportunities [4] - Yang Jinjing emphasizes a contrarian investment approach, seeking undervalued stocks and avoiding following irrational market trends [4][5] Group 4 - Li Xiaoxing believes that the domestic equity market presents more opportunities than risks, with AI continuing to drive technological innovation and domestic internet giants expected to maintain stable growth [7][8] - The domestic consumption sector, which underperformed in 2025, is viewed as having high potential, with many quality consumer stocks offering attractive dividend yields [8] - Long-term prospects for the domestic innovative pharmaceutical sector are positive, with a focus on companies with data catalysts and explosive performance potential [8]